Amarantus receives U.S. patent titled, 'Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof'

Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof. This patent covers the discovery of MANF and its composition of matter and complements the Company's existing portfolio of issued patents and pending patent applications. The key claim allowed under the patent is as follows: A pharmaceutical composition comprising: (i) a substantially purified polypeptide comprising the sequence of SEQ ID NO: 2 (MANF); and (ii) a carrier that is pharmaceutically acceptable for administration to the central nervous system.

"The issuance of this new patent validates the novelty of the science Amarantus is producing and validates the tremendous work our scientific team has put forth over the last several years," said Gerald Commissiong, President and CEO. "We hope to turn this groundbreaking discovery into a game-changing therapy when we ultimately embark on human clinical development for the treatment of Parkinson's disease and other disorders of the Central Nervous System. We intend to continue intellectual property prosecution for MANF in other disease states as well."

Source: Amarantus BioSciences, Inc.